Sitemap
Glycotest
slider1 Slider2

Welcome to Glycotest

Glycotest Diagnostics is developing unique and non-invasive blood tests for liver cancers and fibrosis-cirrhosis. Our technology could revolutionize care and treatment for people at risk due to chronic liver disease—both people with viral hepatitis (chronic hepatitis B and C infections) and the rapidly growing population with non-viral hepatitis due to obesity and metabolic disease.

Latest News

03-09-2019
Glycotest is developing a new Test for Detecting Early Stage Liver Cancer with the revolutionary approach of using Glycoproteins as Biomarkers – CEOCFO Magazine
22-08-2019
Glycotest was chosen as one of 50 companies to be in the MedTech Showcase in September 2019
13-06-2019
Case-Control Study of the Glycotest™ HCC Panel vs AFP For the Detection of Early-stage Hepatocellular Carcinoma (NCT03878550)
14-02-2019
Glycotest, Inc. Receives $3 Million First Tranche of $10 Million Series A Financing
22-10-2018
Glycotest™ Closes $10 Million Series A Financing with Fosun Pharma
04-01-2018
Glycotest™ HCC Panel Completes Successful Clinical Product Evaluation
02-11-2017
Glycotest™ Expands Patent Portfolio with Chinese Patent
05-10-2017
Glycotest™ Announces Grant of Japanese Patent
07-07-2017
Glycotest™ Intellectual Property Portfolio Expanded by United Sates, European and Australian Patents
26-06-2017
Glycotest Update

Key Features

bollet
Exploits unique disease signal chemistry (glycoprotein fucosylation) present in liver cancers and fibrosis-cirrhosis but absent in healthy individuals
bollet
Incorporated into highly promising biomarker panels
bollet
Focused on the detection of potentially curable early-stage disease
bollet
May outperform currently available serum biomarkers, such as AFP
bollet
Targeting the worldwide liver cancer threat that kills more than 700,000 people annually and is the fastest growing cause of cancer death in the US